We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+1.9%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$147M
AUM Growth
-$4.44M
Cap. Flow
+$5.23M
Cap. Flow %
3.56%
Top 10 Hldgs %
90.7%
Holding
22
New
1
Increased
3
Reduced
3
Closed
4

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$16M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$4.9M
3
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$1.24M
4
TPST icon
Tempest Therapeutics
TPST
+$1.17M

Top Sells

Rank Stock Value
1
ALLK
Allakos
ALLK
+$10.5M
2
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$3.12M
3
LQDA icon
Liquidia Corp
LQDA
+$2.98M
4
RGLS
Regulus Therapeutics
RGLS
+$1.13M
5
SURF
Surface Oncology, Inc. Common Stock
SURF
+$221K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICPT
1
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$26.8M 18.23%
403,688
+72,991
+22% +$4.9M
ALLK
2
DELISTED
Allakos
ALLK
$22.6M 15.37%
287,205
-159,700
-36% -$10.5M
SYRS
3
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$17M 11.58%
172,660
– –
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
$14.7M 9.98%
+676,602
New +$16M
ODT
5
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$13.6M 9.26%
522,637
-93,213
-15% -$3.12M
PRNB
6
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$10.8M 7.37%
383,480
– –
STRO icon
7
Sutro Biopharma
STRO
$379M
$10.2M 6.96%
112,558
– –
BCEL
8
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$7.24M 4.93%
591,368
– –
GOSS icon
9
Gossamer Bio
GOSS
$66.5M
$6.32M 4.3%
376,583
– –
HOOK
10
DELISTED
HOOKIPA Pharma
HOOK
$3.98M 2.71%
53,025
– –
ARAV
11
DELISTED
Aravive, Inc. Common Stock
ARAV
$3.32M 2.26%
442,733
– –
VIRX
12
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.6M 1.77%
103,169
+42,857
+71% +$1.24M
ATXS
13
DELISTED
Astria Therapeutics
ATXS
$1.62M 1.1%
50,000
– –
UROV
14
DELISTED
Urovant Sciences Ltd.
UROV
$1.49M 1.01%
157,480
– –
EVLO
15
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$1.39M 0.94%
11,376
– –
KALV
16
DELISTED
KalVista Pharmaceuticals
KALV
$1.38M 0.94%
118,500
– –
TPST icon
17
Tempest Therapeutics
TPST
$14.8M
$1.33M 0.9%
957
+726
+314% +$1.17M
LQDA icon
18
Liquidia Corp
LQDA
$7.67B
$550K 0.37%
154,462
-504,070
-77% -$2.98M
PDSB icon
19
PDS Biotechnology
PDSB
$38.1M
– –
-9,166
Closed -$55K
RGLS
20
DELISTED
Regulus Therapeutics
RGLS
– –
-90,441
Closed -$1.13M
SURF
21
DELISTED
Surface Oncology, Inc. Common Stock
SURF
– –
-78,300
Closed -$221K
TRIL
22
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-71,619
Closed -$24K

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q3 2019 Portfolio in Review

As of Q3 2019, Samsara BioCapital held 22 positions worth $147M, down 2.9% from $151M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Samsara BioCapital deployed $5.23M of net new capital in Q3 2019, opening 1 new position and adding to 3 existing holdings. Its largest new stake was SpringWorks Therapeutics: 676,602 shares worth $14.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Allakos, an estimated $10.5M trimmed.

  • Samsara BioCapital's largest Q3 2019 buy was SpringWorks Therapeutics: 676,602 shares worth $14.7M.
  • Samsara BioCapital added most to Intercept Pharmaceuticals, Inc. in Q3 2019, an estimated $4.9M increase.
  • Samsara BioCapital's biggest Q3 2019 reduction was Allakos, cutting an estimated $10.5M.
  • Samsara BioCapital fully exited Regulus Therapeutics in Q3 2019, selling an estimated $1.13M.
  • Samsara BioCapital's ten largest holdings make up 91% of its $147M portfolio in Q3 2019.
  • Samsara BioCapital opened 1 new position and closed 4 in Q3 2019.
  • Samsara BioCapital's portfolio value fell 2.9% quarter-over-quarter to $147M.

Based on Samsara BioCapital's 13F filing for Q3 2019, filed 14 Nov 2019.